PD-L1 Protein (Fc Tag)

N° du produit ABIN7194771

Cette protéine Recombinant PD-L1 est produite dans HEK-293 Cells.

Aperçu rapide pour PD-L1 Protein (Fc Tag) (ABIN7194771)

Antigène: PD-L1 (CD274 (PD-L1))

Type de proteíne: Recombinant

Activité biologique: Active

Origine: Humain

Source: HEK-293 Cells

Pureté: > 95 % as determined by reducing SDS-PAGE.

Détail du produit

Purification/Conjugué: Cette PD-L1 protéine est marqué à la Fc Tag.

Fonction: Recombinant Human PD-L1/B7-H1/CD274 Protein (Fc Tag)(Active)

Séquence: Met 1-Thr 239

Attributs du produit: A DNA sequence encoding the N-terminal segment (Met 1-Thr 239) of the extracellular domain of human B7-H1 (NP_054862.1) was expressed with C-terminal fused Fc region of human IgG1.

niveau d'endotoxine: < 1.0 EU per μg as determined by the LAL method.

Biological Activity Comment: Measured by its binding ability in a functional ELISA. Immobilized human PD-1 at 10 μg/ml (100 μl/well) can bind recombinant human B7-H1 / PD-L1 / Fc chimera with a linear range of 0.02-0.4 μg/ml.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Please refer to the printed manual for detailed information.

Buffer: Lyophilized from sterile PBS, pH 7.4

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Détail du antigène

Antigène: PD-L1 (CD274 (PD-L1))

Autre désignation: PD-L1/B7-H1/CD274

Sujet:

Background: Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies   Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies   Immune Checkpoint Detection: IHC Antibodies   Immune Checkpoint Detection: ICC Antibodies   Immune Checkpoint Detection: FCM Antibodies   Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins   PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets   Co-inhibitory Immune Checkpoint Targets Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Synonym: Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1

Poids moléculaire: 52 kDa

NCBI Accession: NP_054862

Pathways: Cancer Immune Checkpoints